Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiology
Shipment of disposable thrombin processing device to Biomet subsidiary CFT begun
September 15th, 2005
ThermoGenesis Corp. (KOOL) announced that the company has begun shipping its CE marked TPD (thrombin processing devices) to the Biomet, Inc. (BMET) subsidiary, Cell Factor Technologies, Inc. (CFT). CFT will use the TPD to prepare autologous thrombin while a customized centrifugal thrombin device, named Clotalyst, is under development by ThermoGenesis. The TPD disposable kit, which produces stable, activated thrombin from the patient's own blood in less than 30 minutes, will enable CFT to address this demand in Europe, Canada, and Asia. Approximately $180 million of thrombin annually is consumed worldwide as a blood clotting enzyme that surgeons use...
Source: Women's Health Weekly (2005-09-15)
|
